Boston Scientific Co. (NYSE:BSX) Shares Bought by Raleigh Capital Management Inc.

Raleigh Capital Management Inc. lifted its holdings in Boston Scientific Co. (NYSE:BSX) by 8.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,809 shares of the medical equipment provider’s stock after purchasing an additional 449 shares during the period. Raleigh Capital Management Inc.’s holdings in Boston Scientific were worth $519,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in BSX. AE Wealth Management LLC increased its holdings in shares of Boston Scientific by 18.9% in the second quarter. AE Wealth Management LLC now owns 16,261 shares of the medical equipment provider’s stock valued at $1,252,000 after buying an additional 2,582 shares in the last quarter. Evergreen Capital Management LLC raised its position in shares of Boston Scientific by 28.4% during the second quarter. Evergreen Capital Management LLC now owns 5,950 shares of the medical equipment provider’s stock worth $458,000 after purchasing an additional 1,315 shares during the period. Insigneo Advisory Services LLC raised its position in shares of Boston Scientific by 27.7% during the second quarter. Insigneo Advisory Services LLC now owns 21,959 shares of the medical equipment provider’s stock worth $1,602,000 after purchasing an additional 4,763 shares during the period. Zurich Insurance Group Ltd FI lifted its holdings in shares of Boston Scientific by 57.9% during the second quarter. Zurich Insurance Group Ltd FI now owns 2,047,710 shares of the medical equipment provider’s stock valued at $157,694,000 after purchasing an additional 750,811 shares during the last quarter. Finally, Toronto Dominion Bank boosted its position in shares of Boston Scientific by 23.6% in the 2nd quarter. Toronto Dominion Bank now owns 928,098 shares of the medical equipment provider’s stock valued at $71,473,000 after purchasing an additional 177,006 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BSX shares. Evercore ISI upped their price objective on shares of Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup raised their price objective on shares of Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Morgan Stanley boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a research note on Thursday, October 24th. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Finally, Stifel Nicolaus upped their price target on Boston Scientific from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Three analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $97.26.

Boston Scientific Stock Down 0.6 %

Shares of BSX stock opened at $100.29 on Thursday. The company has a market capitalization of $147.81 billion, a price-to-earnings ratio of 82.88, a PEG ratio of 2.64 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The stock’s 50 day simple moving average is $91.68 and its 200 day simple moving average is $85.04. Boston Scientific Co. has a twelve month low of $59.85 and a twelve month high of $101.65.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same quarter last year, the firm posted $0.50 earnings per share. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. As a group, research analysts predict that Boston Scientific Co. will post 2.46 EPS for the current year.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at approximately $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the sale, the executive vice president now owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,989 shares of company stock worth $2,702,261 in the last quarter. 0.50% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.